PAR2 antagonists—the next generation of anti-inflammatories?

BMJ 2000; 320 doi: 10.1136/bmj.320.7231.334 (Published 5 February 2000)
Cite this as: BMJ 2000;320:334.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Abi Berger
  1. BMJ

    New understanding of how sensory nerve cells transmit their signals to the central nervous system has been reached by researchers at the University of California in San Francisco.

    Nigel Bunnett, professor of surgery and physiology, and his team have shown that tryptase—a degradatory enzyme known to be involved in triggering the inflammatory process—works by activating a new class of receptor called PAR2 (proteinase activated 2 receptors).

    Professor Bunnett's work suggests that substances that block these receptors could make good candidates for new anti-inflammatory drugs (Nature Medicine 2000;6:151-8).

    When sensory …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL